LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Radicicol | 10.0 | uM | LJP6 | 72 | hr | 1311 | 1256 | 5013 | 0.2506 | -0.0150 |
MDA-MB-231 | Seliciclib | 10.0 | uM | LJP5 | 72 | hr | 1311 | 2705 | 5013 | 0.5396 | 0.3765 |
MDA-MB-231 | Ruxolitinib | 10.0 | uM | LJP5 | 72 | hr | 1311 | 4378 | 5013 | 0.8733 | 0.8284 |
MDA-MB-231 | XL147 | 10.0 | uM | LJP5 | 72 | hr | 1311 | 4400 | 5013 | 0.8778 | 0.8344 |
MDA-MB-231 | Saracatinib | 10.0 | uM | LJP6 | 72 | hr | 1311 | 2008 | 5013 | 0.4006 | 0.1882 |
MDA-MB-231 | Selumetinib | 10.0 | uM | LJP6 | 72 | hr | 1311 | 1752 | 5013 | 0.3495 | 0.1189 |
MDA-MB-231 | Sirolimus | 10.0 | uM | LJP6 | 72 | hr | 1311 | 4299 | 5013 | 0.8575 | 0.8070 |
MDA-MB-231 | Sorafenib | 10.0 | uM | LJP6 | 72 | hr | 1311 | 4434 | 5013 | 0.8845 | 0.8435 |
MDA-MB-231 | SU11274 | 10.0 | uM | LJP5 | 72 | hr | 1311 | 1655 | 5013 | 0.3302 | 0.0929 |
MDA-MB-231 | Fedratinib | 10.0 | uM | LJP5 | 72 | hr | 1311 | 642 | 5013 | 0.1281 | -0.1809 |
MDA-MB-231 | TGX221 | 10.0 | uM | LJP5 | 72 | hr | 1311 | 4596 | 5013 | 0.9168 | 0.8873 |
MDA-MB-231 | Torin1 | 10.0 | uM | LJP6 | 72 | hr | 1311 | 1164 | 5013 | 0.2323 | -0.0397 |
MDA-MB-231 | Torin2 | 10.0 | uM | LJP5 | 72 | hr | 1311 | 780 | 5013 | 0.1557 | -0.1435 |
MDA-MB-231 | Tozasertib | 10.0 | uM | LJP5 | 72 | hr | 1311 | 1419 | 5013 | 0.2830 | 0.0290 |
MDA-MB-231 | Trametinib | 10.0 | uM | LJP5 | 72 | hr | 1311 | 1683 | 5013 | 0.3358 | 0.1004 |
MDA-MB-231 | TWS119 | 10.0 | uM | LJP5 | 72 | hr | 1311 | 1542 | 5013 | 0.3076 | 0.0623 |
MDA-MB-231 | Vemurafenib | 10.0 | uM | LJP5 | 72 | hr | 1311 | 2744 | 5013 | 0.5474 | 0.3870 |
MDA-MB-231 | Withaferin A | 10.0 | uM | LJP5 | 72 | hr | 1311 | 466 | 5013 | 0.0929 | -0.2285 |
MDA-MB-231 | Withaferin A | 10.0 | uM | LJP6 | 72 | hr | 1311 | 379 | 5013 | 0.0757 | -0.2519 |
MDA-MB-231 | WYE-125132 | 10.0 | uM | LJP6 | 72 | hr | 1311 | 1436 | 5013 | 0.2865 | 0.0337 |
MDA-MB-231 | WZ3105 | 10.0 | uM | LJP5 | 72 | hr | 1311 | 1027 | 5013 | 0.2049 | -0.0769 |
MDA-MB-231 | XMD11-50 | 10.0 | uM | LJP6 | 72 | hr | 1311 | 1367 | 5013 | 0.2728 | 0.0151 |
MDA-MB-231 | Y39983 | 10.0 | uM | LJP6 | 72 | hr | 1311 | 724 | 5013 | 0.1445 | -0.1586 |
MDA-MB-231 | YM 201636 | 10.0 | uM | LJP5 | 72 | hr | 1311 | 1386 | 5013 | 0.2765 | 0.0202 |
MDA-MB-231 | ZSTK474 | 10.0 | uM | LJP6 | 72 | hr | 1311 | 2522 | 5013 | 0.5032 | 0.3271 |